NYSE$ATNM
Actinium Pharmaceuticals Inc · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Actinium Pharmaceuticals, Inc. reported a net loss of $15.9 million for Q1 2025, an increase from the $8.7 million net loss in Q1 2024, primarily due to higher research and development and general and administrative expenses.
Actinium Pharmaceuticals, Inc. experienced a significant increase in net loss for the first quarter of 2025, reaching $15.9 million compared to $8.7 million in the same period last year. This was primarily driven by higher research and development expenses and increased general and administrative costs, largely due to non-cash stock-based compensation.
- Net loss increased to $15.9 million in Q1 2025 from $8.7 million in Q1 2024.
- Total operating expenses rose to $16.6 million in Q1 2025 from $9.6 million in Q1 2024.
- Research and development expenses, net of reimbursements, increased by $1.1 million, reaching $7.7 million in Q1 2025.
- General and administrative expenses significantly increased by $5.9 million, totaling $8.9 million in Q1 2025, primarily due to higher non-cash stock-based compensation.
Headline financials
Revenue & EPS history
Actinium · Revenue · Quarterly
$0
Forward guidance
Actinium Pharmaceuticals, Inc. expects its existing resources to be sufficient to fund planned operations for more than 12 months from the report date. The company anticipates a reduction in personnel-related expenses for the remainder of 2025 due to a workforce optimization.
Tailwinds
- Existing resources are expected to be sufficient to fund planned operations for more than 12 months.
- Workforce optimization is expected to reduce personnel-related expenses by approximately $1.15 million for the remainder of 2025.
- The company believes it has been successful in attracting skilled and experienced personnel despite competitive hiring market.
- The company continues to engage external consultants on an as-needed basis to temporarily supplement existing staff.
- The company is actively seeking a strategic partner for Iomab-B in the U.S. to advance additional studies and trials required by the FDA.
Headwinds
- The company anticipates continued net losses in the future as it continues research and development efforts, clinical trials, and building manufacturing, sales, marketing, and distribution capabilities.
- The company's business or operations may change in a manner that consumes available funds more rapidly than anticipated, requiring substantial additional funding.
- The company may not be able to secure additional funding on favorable terms or at all, potentially leading to delays or elimination of research and development activities.
- The FDA has determined that the SIERRA trial alone is not adequate to support a BLA filing for Iomab-B, requiring an additional randomized head-to-head clinical trial.
- The U.S. commercial opportunity for Iomab-B may never be realized due to regulatory hurdles and the need for a strategic partner.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2025
+0.8%
Avg return
Earnings day
-2.9%
Avg return
5 days after
+2.0%
Avg return
30 days after
53%
28 / 53 earnings
Positive
+46.5%
Q3 2013
Best reaction
-53.5%
Q2 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -1.4% | -3.8% | -19.8% | |
| Q3 2025 | +14.3% | +1.6% | +25.2% | |
| Q2 2025 | -6.5% | +7.1% | +3.9% | |
| Q1 2025 | +6.0% | +1.8% | -8.4% | |
| Q4 2024 | -0.8% | -4.8% | +32.5% | |
| Q3 2024 | -12.3% | -17.0% | -28.1% | |
| Q2 2024 | -53.5% | -66.8% | -70.8% | |
| Q1 2024 | +12.5% | +18.6% | +29.6% | |
| Q4 2023 | +9.3% | +12.9% | -12.3% | |
| Q3 2023 | -12.2% | -9.6% | -7.0% | |
| Q2 2023 | +1.6% | -3.0% | +5.2% | |
| Q1 2023 | +0.8% | +4.1% | -4.6% | |
| Q4 2022 | -5.2% | -5.0% | -5.1% | |
| Q3 2022 | +3.5% | +0.7% | -7.1% | |
| Q2 2022 | +5.6% | +2.6% | +48.8% | |
| Q1 2022 | +4.2% | +9.4% | -7.8% | |
| Q4 2021 | -2.2% | +1.0% | +35.8% | |
| Q3 2021 | +3.2% | -0.8% | -12.6% | |
| Q2 2021 | +2.1% | -1.9% | -10.5% | |
| Q1 2021 | +6.4% | +6.7% | +21.4% | |
| Q4 2020 | +5.2% | +6.0% | +0.0% | |
| Q3 2020 | -3.0% | -9.4% | -5.6% | |
| Q2 2020 | +9.1% | -2.8% | -14.0% | |
| Q1 2020 | -3.1% | -13.5% | +59.8% | |
| Q4 2019 | +4.8% | +0.0% | +66.7% | |
| Q3 2019 | -0.7% | -0.8% | -18.8% | |
| Q2 2019 | +5.9% | -1.4% | -2.3% | |
| Q1 2019 | -5.8% | -9.1% | -9.1% | |
| Q4 2018 | +1.6% | -3.7% | -5.4% | |
| Q3 2018 | -5.6% | -17.4% | -21.3% | |
| Q2 2018 | +6.5% | +8.8% | +16.7% | |
| Q1 2018 | +2.1% | +5.3% | +20.8% | |
| Q4 2017 | -6.0% | -4.6% | -9.6% | |
| Q3 2017 | -2.0% | -7.8% | +9.6% | |
| Q2 2017 | +0.0% | -7.7% | +0.0% | |
| Q1 2017 | -1.4% | -1.4% | -22.9% | |
| Q4 2016 | +3.0% | +4.5% | +9.7% | |
| Q3 2016 | -8.7% | -10.6% | -2.9% | |
| Q2 2016 | -2.3% | -2.3% | -1.7% | |
| Q1 2016 | +5.2% | — | — | |
| Q4 2015 | +2.1% | — | — | |
| Q3 2015 | -3.7% | — | — | |
| Q2 2015 | -0.9% | — | — | |
| Q1 2015 | +6.0% | — | — | |
| Q4 2014 | +13.5% | — | — | |
| Q3 2014 | +4.1% | — | — | |
| Q2 2014 | +0.0% | — | — | |
| Q1 2014 | +8.8% | — | — | |
| Q4 2013 | +2.0% | — | — | |
| Q3 2013 | +46.5% | — | — | |
| Q2 2013 | +0.0% | — | — | |
| Q1 2013 | -1.3% | — | — | |
| Q4 2012 | -15.3% | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro